Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758073 | 0.73 | KDM4E (0.39) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL27934868 | 0.73 | KDM4E (0.39) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL8090871 | 0.66 | MAPT (0.48) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL8089058 | 0.66 | KDM4E (0.48) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL27291567 | 0.66 | KDM4E (0.48) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL6305681 | 0.66 | KDM4E (0.34) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL28517500 | 0.66 | MAPT (0.48) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL29408147 | 0.64 | GAA (0.54) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL29144954 | 0.64 | GAA (0.54) | KDM4EMEN1NPC1GAAMAPT | |
| SCHEMBL17758261 | 0.62 | GAA (0.52) | KDM4EMEN1NPC1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585928-B2 | monomers of acetylenic homo- or copolymers; cured polymers has low dielectric constant as insulating layers in microelectronic devices | DOW GLOBAL TECHNOLOGIES (US) | 2009-09-08 | — | — | US | disclosed |
| US-20070027278-A1 | Multifunctional monomers containing bound mesogenic poragen forming moieties and polyarylene compositions therefrom | DOW GLOBAL TECHNOLOGIES LLC | 2007-02-01 | — | — | US | disclosed |
| WO-2005042613-A1 | MULTIFUNCTIONAL MONOMERS CONTAINING BOUND MESOGENIC PORAGEN FORMING MOIETIES AND POLYARYLENE COMPOSITIONS THEREFROM | DOW GLOBAL TECHNOLOGIES INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-5637669-A | THERMOSETTING RESIN; LIQUID CRYSTALLINE POLYMERS | THE DOW CHEMICAL COMPANY (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0670856-A1 | THERMOSETTABLE COMPOSITION CONTAINING MESOGENIC MOIETIES | THE DOW CHEMICAL COMPANY (US) | 1995-09-13 | — | — | EP | disclosed |
| WO-1994012556-A2 | THERMOSETTABLE COMPOSITION CONTAINING DISCOTIC MESOGENIC MOIETIES | THE DOW CHEMICAL COMPANY (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027278-A1 | Multifunctional monomers containing bound mesogenic poragen forming moieties and polyarylene compositions therefrom | LRBA, CD74, BMP2 | KDM4E 4789/4885MEN1 443/4885NPC1 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.